Carolyn A Young

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8016778/publications.pdf

Version: 2024-02-01

117 papers	5,187 citations	109137 35 h-index	95083 68 g-index
117 all docs	117 docs citations	117 times ranked	5857 citing authors

#	Article	IF	Citations
1	Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 2005, 65, 812-819.	1.5	583
2	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 374, 1503-1511.	6.3	551
3	Achieving Saturation in Thematic Analysis: Development and Refinement of a Codebook. Comprehensive Psychology, 2014, 3, 03.CP.3.4.	0.3	275
4	Oromucosal Î”9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clinical Therapeutics, 2007, 29, 2068-2079.	1.1	173
5	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015, 15, 273-279.	0.5	169
6	A medical definition of fatigue in multiple sclerosis. QJM - Monthly Journal of the Association of Physicians, 2007, 101, 49-60.	0.2	132
7	A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1225-1230.	0.9	121
8	Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 339-345.	4.9	118
9	Rasch analysis of the hospital anxiety and depression scale (hads) for use in motor neurone disease. Health and Quality of Life Outcomes, 2011, 9, 82.	1.0	96
10	Rasch analysis of the Fatigue Severity Scale in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 81-87.	1.4	95
11	Development of a patient reported outcome scale for fatigue in multiple sclerosis: The Neurological Fatigue Index (NFI-MS). Health and Quality of Life Outcomes, 2010, 8, 22.	1.0	88
12	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis Journal, 2013, 19, 1074-1083.	1.4	87
13	Development and validation of a self-efficacy measure for people with multiple sclerosis: the Multiple Sclerosis Self-efficacy Scale. Multiple Sclerosis Journal, 2003, 9, 73-81.	1.4	85
14	The relationship between fatigue and other clinical features of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 604-612.	1.4	83
15	Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology, 2017, 89, 1915-1922.	1.5	82
16	Treatment for ataxia in multiple sclerosis. The Cochrane Library, 2007, , CD005029.	1.5	77
17	Perceptions of self-efficacy and rehabilitation among neurologically disabled adults. Clinical Rehabilitation, 2007, 21, 230-240.	1.0	76
18	Rasch analysis of the Modified Fatigue Impact Scale (MFIS) in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1049-1051.	0.9	76

#	Article	IF	Citations
19	Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 45-49.	0.9	75
20	A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. Clinical Rehabilitation, 2006, 20, 783-792.	1.0	72
21	Assessment of depression in patients with motor neuron disease and other neurologically disabling illness. Journal of the Neurological Sciences, 1997, 152, s75-s79.	0.3	66
22	The role of affect on the perception of disability in multiple sclerosis. Clinical Rehabilitation, 2000, 14, 50-54.	1.0	61
23	A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 246-249.	0.9	61
24	Comparison of the Kingâ€™s and MiToS staging systems for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 227-232.	1.1	58
25	HLA-DRB1 and disease outcome in multiple sclerosis. Journal of Neurology, 2001, 248, 304-310.	1.8	56
26	Measuring the impact of multiple sclerosis on psychosocial functioning: the development of a new self-efficacy scale. Clinical Rehabilitation, 2001, 15, 259-265.	1.0	53
27	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Multiple Sclerosis Journal, 2007, 13, 502-508.	1.4	53
28	Central trigeminal involvement in multiple sclerosis using high-resolution MRI at 3 T. British Journal of Radiology, 2010, 83, 493-498.	1.0	53
29	Anticholinergics for urinary symptoms in multiple sclerosis. , 2009, , CD004193.		50
30	Disability after encephalitis: development and validation of a new outcome score. Bulletin of the World Health Organization, 2010, 88, 584-592.	1.5	50
31	Spasticity in multiple sclerosis: Associations with impairments and overall quality of life. Multiple Sclerosis and Related Disorders, 2016, 5, 34-39.	0.9	46
32	A randomized group intervention trial to enhance mood and selfâ€efficacy in people with multiple sclerosis. British Journal of Health Psychology, 2008, 13, 619-631.	1.9	45
33	Perceptions of goal setting in a neurological rehabilitation unit: A qualitative study of patients, carers and staff. Acta Dermato-Venereologica, 2008, 40, 190-194.	0.6	45
34	Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions. Disability and Rehabilitation, 2016, 38, 1431-1441.	0.9	44
35	How integrated are neurology and palliative care services? Results of a multicentre mapping exercise. BMC Neurology, 2016, 16, 63.	0.8	41
36	Validation and Reliability of the Neuropathic Pain Scale (NPS) in Multiple Sclerosis. Clinical Journal of Pain, 2007, 23, 473-481.	0.8	40

#	Article	IF	Citations
37	Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2017, 2017, CD011776.	1.5	39
38	Quality of life issues in motor neurone disease: the development and validation of a coping strategies questionnaire, the MND Coping Scale. Journal of the Neurological Sciences, 2001, 191, 79-85.	0.3	35
39	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	1.1	35
40	Vitamin D receptor gene polymorphism is associated with reduced disability in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1280-1283.	1.4	34
41	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	1.4	34
42	Obstructive sleep apnoea with Arnold-Chiari malformation.. Thorax, 1995, 50, 690-697.	2.7	33
43	How does current care practice influence the experience of a new diagnosis of motor neuron disease? A qualitative study of current guidelinesâ€based practice. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 161-166.	2.3	32
44	Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. The Cochrane Library, 2011, , CD006981.	1.5	32
45	Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND). Health and Quality of Life Outcomes, 2011, 9, 101.	1.0	31
46	The impact of fatigue and psychosocial variables on quality of life for patients with motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 537-545.	1.1	31
47	Why don't they accept nonâ€invasive ventilation?: Insight into the interpersonal perspectives of patients with motor neurone disease. British Journal of Health Psychology, 2015, 20, 341-359.	1.9	31
48	Worries and concerns of patients with multiple sclerosis: development of an assessment scale. Multiple Sclerosis Journal, 2006, 12, 196-203.	1.4	30
49	The patient experience of fatigue in motor neurone disease. Frontiers in Psychology, 2013, 4, 788.	1.1	29
50	Management of sialorrhoea in motor neuron disease: A survey of current UK practice. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 521-527.	1.1	28
51	Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation. Multiple Sclerosis Journal, 2007, 13, 369-375.	1.4	27
52	The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 317-327.	1.1	27
53	Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 285-291.	1.1	26
54	Effect of Short-term Integrated Palliative Care on Patient-Reported Outcomes Among Patients Severely Affected With Long-term Neurological Conditions. JAMA Network Open, 2020, 3, e2015061.	2.8	26

#	Article	IF	Citations
55	The effects of an 'exercise and education' programme on exercise self-efficacy and levels of independent activity in adults with acquired neurological pathologies: an exploratory, randomized study. Clinical Rehabilitation, 2009, 23, 371-383.	1.0	25
56	The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome. Multiple Sclerosis Journal, 2012, 18, 1326-1333.	1.4	25
57	Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature. Journal of Neurology, 2020, 267, 607-615.	1.8	25
58	Quality of life assessment in MND: development of a Social Withdrawal Scale. Journal of the Neurological Sciences, 1999, 169, 26-34.	0.3	24
59	Validation of the Neurological Fatigue Index for stroke (NFI-Stroke). Health and Quality of Life Outcomes, 2012, 10, 51.	1.0	24
60	Sexual functioning in multiple sclerosis: Relationships with depression, fatigue and physical function. Multiple Sclerosis Journal, 2017, 23, 1268-1275.	1.4	24
61	Building a care and research team. Journal of the Neurological Sciences, 1998, 160, S137-S140.	0.3	23
62	Poststroke Fatigue: The Patient Perspective. Topics in Stroke Rehabilitation, 2013, 20, 478-484.	1.0	23
63	Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2018, 2018, CD011005.	1.5	22
64	Disease progression and perceptions of health in patients with motor neurone disease. Journal of the Neurological Sciences, 1995, 129, 50-53.	0.3	21
65	A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 1-9.	1.1	20
66	Experience of telehealth in people with motor neurone disease using noninvasive ventilation. Disability and Rehabilitation: Assistive Technology, 2021, 16, 490-496.	1.3	20
67	Development of a patient-specific dyspnoea questionnaire in motor neurone disease (MND): the MND dyspnoea rating scale (MDRS). Journal of the Neurological Sciences, 2000, 180, 86-93.	0.3	19
68	Factors predisposing to the development of multiple sclerosis. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 383-386.	0.2	19
69	Perceived changes and minimum clinically important difference of the Neurological Fatigue Index for multiple sclerosis (NFI-MS). Multiple Sclerosis Journal, 2013, 19, 502-505.	1.4	19
70	Experience of long-term use of non-invasive ventilation in motor neuron disease: an interpretative phenomenological analysis. BMJ Supportive and Palliative Care, 2014, 4, 50-56.	0.8	19
71	Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. Journal of the Neurological Sciences, 2021, 426, 117437.	0.3	19
72	Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert Opinion on Drug Safety, 2010, 9, 905-915.	1.0	18

#	Article	IF	Citations
73	Health Utilities and Costs for Motor Neurone Disease. Value in Health, 2019, 22, 1257-1265.	0.1	17
74	3D MRI in multiple sclerosis: a study of three sequences at 3 T. British Journal of Radiology, 2007, 80, 307-320.	1.0	16
75	Sporadic Creutzfeldt Jakob disease in two adolescents. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 14-18.	0.9	16
76	Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]. BMC Neurology, 2011, 11, 111.	0.8	16
77	Determinants of accepting non-invasive ventilation treatment in motor neurone disease: a quantitative analysis at point of need. Health Psychology and Behavioral Medicine, 2013, 1, 47-58.	0.8	16
78	The WHOQOL-BREF: a modern psychometric evaluation of its internal construct validity in people with multiple sclerosis. Quality of Life Research, 2020, 29, 1961-1972.	1.5	15
79	Multiple sclerosis: Care needs for 2000 and beyond. Journal of the Royal Society of Medicine, 2000, 93, 219-224.	1.1	14
80	Rasch analysis of the WHOQOL-BREF in post polio syndrome. Journal of Rehabilitation Medicine, 2013, 45, 873-880.	0.8	14
81	Rasch analysis of SFâ€Qualiveen in multiple sclerosis. Neurourology and Urodynamics, 2017, 36, 1161-1166.	0.8	14
82	Identifying poor adaptation to a new diagnosis of motor neuron disease: A pilot study into the value of an early patient-led interview. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 104-109.	2.3	13
83	Is the Epworth Sleepiness Scale Suitable for Use in Stroke?. Topics in Stroke Rehabilitation, 2013, 20, 493-499.	1.0	13
84	Risk factors for social withdrawal in amyotrophic lateral sclerosis/motor neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 591-598.	1.1	11
85	Incorporating self-reported questions for telemonitoring to optimize care of patients with MND on noninvasive ventilation (MND OptNIVent). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 336-347.	1.1	11
86	Detection of hearing impairment and handicap in Paget's disease of bone using a simple scoring system: A case control study. Bone, 2007, 40, 189-193.	1.4	10
87	Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. Value in Health, 2018, 21, 1322-1329.	0.1	9
88	Exploring and Addressing â€˜Concernsâ€™ for Significant Others to Extend the Understanding of Quality of Life With Amyotrophic Lateral Sclerosis: A Qualitative Study. Journal of Central Nervous System Disease, 2019, 11, 117957351985936.	0.7	9
89	Assessing social isolation in motor neurone disease: A Rasch analysis of the MND Social Withdrawal Scale. Journal of the Neurological Sciences, 2013, 334, 112-118.	0.3	8
90	Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis. Acta Neurologica Scandinavica, 2018, 138, 47-54.	1.0	7

#	Article	IF	Citations
91	The Edinburgh Cognitive and Behavioral ALS Screen (ECAS) in frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 606-613.	1.1	7
92	Is NIPA1-associated hereditary spastic paraplegia always â€˜pureâ€™? Further evidence of motor neurone disease and epilepsy as rare manifestations. Neurogenetics, 2020, 21, 305-308.	0.7	7
93	Adverse cognitive effects of phenytoin in severe brain injury: A case report. Brain Injury, 2011, 25, 634-637.	0.6	5
94	Economic Studies in Motor Neurone Disease: A Systematic Methodological Review. Pharmacoeconomics, 2017, 35, 397-413.	1.7	5
95	Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 364-372.	1.1	5
96	Quality of life for post-polio syndrome: a patient derived, Rasch standard scale. Disability and Rehabilitation, 2018, 40, 597-602.	0.9	4
97	Immediate versus delayed short-term integrated palliative care for advanced long-term neurological conditions: the OPTCARE Neuro RCT. Health Services and Delivery Research, 2020, 8, 1-80.	1.4	4
98	Fatigue and anxiety mediate the effect of dyspnea on quality of life in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 390-398.	1.1	4
99	Understanding quality of life across different clinical subtypes of multiple sclerosis: a thematic analysis. Quality of Life Research, 2021, , 1.	1.5	4
100	Assessing and managing depression and fatigue in motor neuron disease. Neurodegenerative Disease Management, 2012, 2, 401-409.	1.2	3
101	Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 442-447.	1.1	3
102	The Neurological Sleep Index: A suite of new sleep scales for multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731664226.	0.5	3
103	Flexibility to manage and enhance quality of life among people with motor neurone disease. Disability and Rehabilitation, 2022, 44, 2752-2762.	0.9	3
104	Tumefactive demyelination: an unusual cause of a spontaneously resolving homonymous hemianopia. BMJ Case Reports, 2013, 2013, bcr2013009363-bcr2013009363.	0.2	3
105	Opsoclonus-myoclonus syndrome: an autopsy study of three cases. The European Journal of Medicine, 1993, 2, 239-41.	0.1	3
106	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. Journal of the Neurological Sciences, 2022, 436, 120188.	0.3	3
107	Treatment for fatigue in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). The Cochrane Library, 2014, , .	1.5	2
108	Assessment of health needs in multidisciplinary care. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 5-5.	0.9	1

#	Article	IF	Citations
109	Minocycline for amyotrophic lateral sclerosis or motor neuron disease. The Cochrane Library, 2007, , .	1.5	1
110	Use of coping strategies in MND/ALS: Association with demographic and diseaseâ€related characteristics. Acta Neurologica Scandinavica, 2019, 140, 131-139.	1.0	1
111	Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis. The Cochrane Library, 2020, , .	1.5	1
112	Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 66-75.	1.1	1
113	Circle of Willis variation in a complex stroke presentation: a case report. BMC Neurology, 2006, 6, 13.	0.8	0
114	P156 Does analysis of patient-ventilator interaction offer benefits in addition to overnight pulse oximetry in patients with motor neurone disease being followed on non-invasive ventilation?. Thorax, 2010, 65, A144-A144.	2.7	0
115	Letter to the editor re: Worsening disability status in multiple sclerosis predicts urologic complications. Int Urol Nephrol. May; 52(5):859â€“863. doi: 10.1007/s11255-020-02381-6. Epub 2020 Jan 25 by Abello et al. International Urology and Nephrology, 2020, 52, 2307-2308.	0.6	0
116	Measuring coping in people with amyotrophic lateral sclerosis using the Coping Index-ALS: A patient derived, Rasch compliant scale. Journal of the Neurological Sciences, 2021, 421, 117285.	0.3	0
117	Letter to the editor re: the effect ofÂpelvic floor exercise program onÂincontinence andÂsexual dysfunction inÂmultiple sclerosis patients Altunan et al., IJUN, (2021) 53:1059. International Urology and Nephrology, 2021, 53, 2297-2298.	0.6	0